Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 June 2024 | Story Precious Shamase | Photo Supplied
Prof Richard Ocaya
Prof Richard Ocaya, Associate Professor from the Physics Department.

Prof Richard Ocaya from the Faculty of Natural and Agricultural Sciences at the University of the Free State (UFS) Qwaqwa  Campus has achieved a significant milestone with a newly patented invention. This patent, developed in collaboration with researchers from Turkey and Saudi Arabia, is the result of work that began in 2017, focusing on a special material known as graphitic carbon nitride.

This breakthrough in temperature measurement technology aligns perfectly with the university's Vision 130 commitment to innovation and addressing global challenges. The new device offers a unique solution to a longstanding issue in the field, providing accurate temperature measurements across an extremely wide range. Existing solutions often require multiple devices, leading to increased costs and reduced accuracy, but this invention simplifies the process.

The device, based on a combination of graphitic carbon nitride and silicon, can measure temperatures from -250°C to 250°C with exceptional consistency and linearity. This range and accuracy set it apart from current technologies, making it suitable for various applications, from standard temperature measurement to specialized settings involving extreme temperatures. It could be especially valuable in deep-space exploration, where equipment faces drastic temperature fluctuations.

The patent underscores the university's commitment to fostering collaborative research, a key aspect of Vision 130. Prof Ocaya attributes the success of the invention to the robust nature of the team, established in 2015. The team is now seeking to commercialize the technology by licensing it to a suitable partner, with organizations like NASA expected to show significant interest.

Prof Ocaya advises other academics considering patenting their inventions to ensure the patent solves a real problem uniquely and is based on sound principles. This makes the invention reproducible and protects it from being copied, assigning exclusive rights to the patent holder. Patenting allows for either manufacturing the devices or licensing them to third parties for royalties and profit. He notes that the main consideration is that the innovation must be practical and solve a specific problem in a novel and commercially viable way. He also acknowledges the challenge many academics face, as the "publish or perish" mentality often leads to choosing scientific articles over patents.

Despite securing the patent, Prof Ocaya and his team continue their research efforts, exploring new possibilities while balancing practical research with academic pursuits. He believes the invention will significantly impact the field of temperature measurement, being integrated into many new designs requiring such measurements.

The university proudly supports this innovative research and anticipates its real-world impact, furthering Vision 130's commitment to increasing UFS's research capacity and capability.

News Archive

National Department of Health invests R53.5 million in UFS laboratory
2016-02-04

Description: Dr Derek Litthauer Tags: Dr Derek Litthauer

Dr Derek Litthauer
Photo: Supplied

This year has started off on a high note for Dr Derek Litthauer and his team at the South African National Control Laboratory (NCL) for Biological Products. The National Department of Health has awarded the NCL a contract to the value of R53.5 million to continue testing vaccines for the next three years.

Vaccines are biological medicines used to ensure healthy populations by preventing many diseases. The World Health Organization (WHO) estimates that, worldwide, about 5.2 million children under six years old die annually. Of these deaths, 29% are vaccine preventable. Research has revealed that vaccines prevent about 6 million deaths each year globally. Safe and effective vaccines are essential public health tools, which are strictly regulated internationally. It is the NCL’s responsibility to perform quality control testing on all vaccines to be used on humans in South Africa.

This laboratory, the only one of its kind in Africa, receives samples of vaccines from manufacturers and importers for rigorous evaluation and testing. No vaccine may be used in South Africa without a release certificate issued by the Control Lab, certifying that the vaccine is suitable for human use.

The contract is a commitment to ensuring that only vaccines of the highest quality are used in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept